Literature DB >> 26319055

Cardiomyocyte H9c2 cells present a valuable alternative to fish lethal testing for azoxystrobin.

Elsa T Rodrigues1, Miguel  Pardal2, Vincent Laizé3, M Leonor Cancela4, Paulo J Oliveira5, Teresa L Serafim6.   

Abstract

The present study aims at identifying, among six mammalian and fish cell lines, a sensitive cell line whose in vitro median inhibitory concentration (IC50) better matches the in vivo short-term Sparus aurata median lethal concentration (LC50). IC50s and LC50 were assessed after exposure to the widely used fungicide azoxystrobin (AZX). Statistical results were relevant for most cell lines after 48 h of AZX exposure, being H9c2 the most sensitive cells, as well as the ones which provided the best prediction of fish toxicity, with a LC50,96h/IC50,48h = 0.581. H9c2 cell proliferation upon 72 h of AZX exposure revealed a LC50,96h/IC50,72h = 0.998. Therefore, identical absolute sensitivities were attained for both in vitro and in vivo assays. To conclude, the H9c2 cell-based assay is reliable and represents a suitable ethical alternative to conventional fish assays for AZX, and could be used to get valuable insights into the toxic effects of other pesticides.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alternative assays; Aquatic ecotoxicology; Azoxystrobin; Cell-based assays; Cytotoxicity; SRB assay

Mesh:

Substances:

Year:  2015        PMID: 26319055     DOI: 10.1016/j.envpol.2015.08.026

Source DB:  PubMed          Journal:  Environ Pollut        ISSN: 0269-7491            Impact factor:   8.071


  2 in total

1.  Cell-based assays as an alternative for the study of aquatic toxicity of pharmaceuticals.

Authors:  Elsa T Rodrigues; Ana T Varela; Miguel A Pardal; Vilma A Sardão
Journal:  Environ Sci Pollut Res Int       Date:  2019-12-27       Impact factor: 4.223

2.  Afrostyrax lepidophyllus Mildbr. and Monodora myristica (Gaertn.) Dunal Extracts Decrease Doxorubicin Cytotoxicity on H9c2 Cardiomyoblasts.

Authors:  Bruno M Moukette; José P Castelão-Baptista; Luciana Ferreira; Ana M Silva; Rui F Simões; Célia Cabral; Constant A Pieme; Jeanne Y Ngogang; Vilma A Sardão; Paulo J Oliveira
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-22       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.